ScienceDirect

Solve M.E. Announces Emily Taylor as New President and CEO and Publication of New White Paper Calling for NIH to Restructure Funding for ME/CFS, Long Covid, and other IACCIs

Retrieved on: 
Monday, April 8, 2024
Engagement, STAT, Postural orthostatic tachycardia syndrome, The Washington Post, POTS, Patient, Public, COVID-19, Research, Black, Volunteering, NIH, News, Business News, ScienceDirect, PTLDS, M.E, Management

Emily has been a key member of Solve's leadership team for more than eight years and played a critical role in securing $1.25 billion RECOVER NIH funding for Long Covid research.

Key Points: 
  • Emily has been a key member of Solve's leadership team for more than eight years and played a critical role in securing $1.25 billion RECOVER NIH funding for Long Covid research.
  • Solve Board Chair John Nicols states, "We congratulate Emily and look forward to her leadership."
  • Solve also announces the publication of their newest white paper, co-authored by Emily, " A Home for Infection-Associated Chronic Conditions and Illnesses (IACCIs) at NIH ."
  • BIPOC (Black, Indigenous, and other People of Color), Latino/Latina, LGBTQIA+, and marginalized, underserved and economically disadvantaged populations are disproportionately impacted by IACCIs.

WINDMILL, THE IPHONE OF AIR CONDITIONING, LAUNCHES STATE-OF-THE-ART AIR CIRCULATOR + FAN

Retrieved on: 
Tuesday, March 19, 2024
Smartphone, High, Butter, Air conditioning, White, Research, Software, Pink, Fan, CFM, AC, The Home Depot, ScienceDirect, ACS, Wayfair, Multimedia, Android, Navy

Just in time for Spring and Summer, the brand has launched their latest smart innovation - The Windmill Air Circulator and Fan - marking yet another milestone in their industry-shaping journey.

Key Points: 
  • Just in time for Spring and Summer, the brand has launched their latest smart innovation - The Windmill Air Circulator and Fan - marking yet another milestone in their industry-shaping journey.
  • Windmill's latest product, The Windmill Air Circulator and Fan, was designed with 5 speeds and versatility in mind.
  • An air circulator can help better distribute cool air from air conditioners around the room, eliminating cold and warm spots and ensuring even comfort throughout the whole room.
  • You can also use an air circulator and fan to distribute warm air around a room in the winter.

Meet Eldie—The Only Gummy on The Market With High Potency, Zero Refined or Artificial Sweeteners, AND American-Grown Organic Elderberries

Retrieved on: 
Thursday, February 8, 2024
Honey, Sambucus, Taylor & Francis, Education, NIH, LEAP, Small business, Trust, Box, Flower, Drink, Inflammation, MDPI, Monterey Bay, Polyphenol, Heart, Health, Iron, COVID-19, EBSCO, Human, Antioxidant, Farmer, Fruit, BMC, WBEC, Calcium, PubMed Central, Super Bowl, ScienceDirect, Coffee

Eldie joins the CA-based company’s line of fresh-pressed, American-grown culinary and wellness products, including: immune syrups, preserves, teas, and balsamic vinegars.

Key Points: 
  • Eldie joins the CA-based company’s line of fresh-pressed, American-grown culinary and wellness products, including: immune syrups, preserves, teas, and balsamic vinegars.
  • “While the process of crafting the immune gummy took more than 12 months, I refused to compromise on anything,” said Reneker.
  • “Our Eldies are made using top-notch sourcing; have 3X the amount of American-grown organic elderberries per serving than many leading brands on the market; contain only natural, zero-refined sweeteners; and incorporate more sustainable packaging.
  • An immune gummy you can feel really good about including in your family’s and your own daily wellness routine.”
    Eldie—The Gummy That Checks All The Boxes!

Lucio N. Gordan, MD is Lead Author of First Real-World Study Comparing Preferred Treatments for Multiple Myeloma

Retrieved on: 
Wednesday, November 22, 2023
Bone marrow, End organ damage, Immune system, Food, Multiple myeloma, DRD, Progression-free survival, Risk, FCS, Clinical trial, TIE, Patient, PFS, Lenalidomide, Death, HIV disease progression rates, Vaccine, Pharmaceutical industry, Dexamethasone, ScienceDirect

FORT MYERS, Fla., Nov. 22, 2023 /PRNewswire/ -- Medical oncologist Lucio N. Gordan MD, president and managing physician of Florida Cancer Specialists & Research Institute, LLC (FCS), is lead author of the first real-world study comparing the two preferred regimens recommended for the primary treatment of non-transplant patients with newly-diagnosed multiple myeloma, published recently in Science Direct. Results of the study to assess optimal clinical treatment strategies were reported in the article entitled, "Progression-Free Survival of Daratumumab (DRd) Versus Bortezomib Triplet Combination With Lenalidomide and Dexamethasone (VRd) in Transplant Ineligible Patients (TIE) With Newly Diagnosed Multiple Myeloma (NDMM): TAURUS Chart Review Study."

Key Points: 
  • Results of the study to assess optimal clinical treatment strategies were reported in the article entitled, "Progression-Free Survival of Daratumumab (DRd) Versus Bortezomib Triplet Combination With Lenalidomide and Dexamethasone (VRd) in Transplant Ineligible Patients (TIE) With Newly Diagnosed Multiple Myeloma (NDMM): TAURUS Chart Review Study."
  • However, previous to the TAURUS study, no direct head-to-head clinical trial had been conducted to compare the efficacy of the two regimens.
  • Cancerous tumors can weaken the body's immune system, damage bones and lead to end-organ damage.
  • MM is the second most common hematologic malignancy in the U.S. Two thirds of newly diagnosed patients are 65 years or older.

Digital Health Solution, Dentistry.One, Bridges the Gap Between Dental and Medical Care for Improved Health and Lower Costs - Visit Us at HLTH 2023

Retrieved on: 
Friday, October 6, 2023
Cardiology, Practice Management, Telemedicine, Virtual Medicine, Oncology, Health, Diabetes, Medical Devices, Dental, Organization, Pregnancy, Booth, Patient, Dentistry, ScienceDirect

“We are excited to demonstrate how Dentistry.One is digitally bridging the gap that has existed for far too long between dental and medical care,” continued Herman.

Key Points: 
  • “We are excited to demonstrate how Dentistry.One is digitally bridging the gap that has existed for far too long between dental and medical care,” continued Herman.
  • Care Advisors make the patient journey seamless with personalized care coordination to in-office appointments, assistance with benefits navigation, and oral health coaching.
  • In addition, Dentistry.One increases patient engagement in oral health through data-driven educational campaigns tailored to address specific health topics aligned with individual needs.
  • To schedule time to speak with us about Dentistry.One during HLTH 2023, please click here .

Sonfu Digital Solutions Announces Health & Wellness Client Reactivation System

Retrieved on: 
Wednesday, September 20, 2023
Advertising, Probability, Marketing, The Heights, Digital Solutions, Research, ScienceDirect, Acquisition, Health, SMS, Sales

Sonfu Digital Solutions LLC has announced its Wellness Accelerated System, a marketing tool that focuses on customer reactivation for companies in the health and wellness sector.

Key Points: 
  • To view an enhanced version of this graphic, please visit:
    In a recent report from Sonfu Digital Solutions, the company explains how customer reactivation is far more cost-effective than customer acquisition.
  • Aimed at health and wellness business owners, Sonfu Digital Solution's reactivation system considers factors such as length of inactivity, purchase history and demographics when contacting inactive customers.
  • Sonfu Digital Solutions was founded by Sonnie Donaby, a digital marketing expert, who started off his career supporting small businesses with the creation of websites and e-commerce shops.
  • Donaby now helps health and wellness business owners integrate digital marketing solutions, such as the Wellness Accelerated System, to reach their goals, and the latest announcement reflects this commitment.

Beyond Air® Announces Publication of Positive New Preclinical Data for the Treatment of Autism Spectrum Disorder

Retrieved on: 
Monday, September 18, 2023
Faculty, Injection, Al-Quds, Hebrew University of Jerusalem, Medical school, Therapy, ScienceDirect, Doctor of Philosophy, Social, Pharming, Autism spectrum, HUJI, Nitric oxide, DSM-IV codes, Research, NOS1, Behavior, Assistant, UCL, Plasma, NO, Patient, ASD, School, Spectrum, Effect, Memory, Nitrogen oxide, Phenotype, Yissum Research Development Company of the Hebrew University, Pharmaceutical industry, Pharmacy, Medicine

GARDEN CITY, N.Y., Sept. 18, 2023 (GLOBE NEWSWIRE) -- Beyond Air, Inc. (NASDAQ: XAIR) (“Beyond Air” or the “Company”) a commercial stage medical device and biopharmaceutical company focused on harnessing the power of endogenous and exogenous nitric oxide (NO) to improve the lives of patients suffering from respiratory illnesses, neurological disorders and solid tumors (through its affiliate Beyond Cancer, Ltd. (“Beyond Cancer”)), today announced the publication of new data that support ongoing preclinical development of selective nNOS inhibitors for the treatment of Autism Spectrum Disorder (ASD).

Key Points: 
  • The slow-release formulation led to reversal of behavioral phenotypes and the nitrosative stress of the Shank3 mouse model of autism.
  • The Hebrew University of Jerusalem (HUJI) has previously published studies suggesting that NO is a pathologic factor in ASD.
  • In previously published studies, 10-day daily injections of 7-nitroindazole (7-NI), a selective nNOS inhibitor, reversed the manifestations of ASD phenotype, and reversed nitrosative stress.
  • “These novel data provide new evidence of the role of nitric oxide in autism.

The DEAL Consortium and Elsevier Announce Transformative Open Access Agreement for Germany

Retrieved on: 
Wednesday, September 6, 2023
Communication, ScienceDirect, North Pacific Marine Science Organization, Freie Erde, Research, Science, Organization, Cell Press, DEAL, Publication, MBH, Reading, Cell, Deals, Knowledge, Pharmaceutical industry, Publishing, Elsevier, Lancet

Berlin, Germany--(Newsfile Corp. - September 6, 2023) - The DEAL Consortium , representing the German research institutions, and Elsevier , a global leader in scientific information and data analytics, are delighted to announce a transformative open access agreement for Germany.

Key Points: 
  • Berlin, Germany--(Newsfile Corp. - September 6, 2023) - The DEAL Consortium , representing the German research institutions, and Elsevier , a global leader in scientific information and data analytics, are delighted to announce a transformative open access agreement for Germany.
  • In addition, institutions will receive discounts on the list prices for their researchers' publications in fully open access Elsevier journals.
  • The agreement fulfils the key objectives set out by the Alliance of Science Organizations in Germany for the DEAL negotiations in enabling open access publishing and reading across Elsevier’s portfolio.
  • The DEAL Consortium and Elsevier worked together collaboratively and pragmatically to support Germany’s world-leading academic and science organizations achieve their research goals for the benefit of society.

Technological Innovations and Diabetes Prevalence Fueling Growth in the 2023 Global Advanced Wound Care Market

Retrieved on: 
Thursday, August 31, 2023
ScienceDirect, Prevalence, Diabetes, Amputation, Center for Economic Studies (U.S. Census Bureau), Foot, Fatality, Cell, Incidence, United States Census Bureau, Chronic condition, Patient, World Health Organization, Conditional sentence, Growth, Ageing, WHO, Death, Notifiable disease, Wound healing, Nursing, Pharmaceutical industry

The global advanced wound care market is poised for remarkable growth in the upcoming forecast period.

Key Points: 
  • The global advanced wound care market is poised for remarkable growth in the upcoming forecast period.
  • The growing prevalence of chronic diseases is a key driver for the global advanced wound care market.
  • The global advanced wound care market is set to experience significant technological advancements in its products.
  • The prevalence of diabetes globally further stimulates the advanced wound care market.

NanoVibronix Cites Positive Results from Independent Testing of UroShield

Retrieved on: 
Wednesday, August 30, 2023
Medical Devices, Health, Health Technology, Clinical Trials, Research, Science, Proteus mirabilis, University, Use, ScienceDirect, Urine, SAW, Infection, Patient, Risk, United Kingdom, CAUTI, Bacteria, Catheter-associated urinary tract infection, Medical imaging, Medical device, Proteus

NanoVibronix, Inc. (NASDAQ: NAOV), a medical device company that produces the UroShield®, PainShield® and WoundShield® Surface Acoustic Wave (SAW) Portable Ultrasonic Therapeutic Devices, today cited positive reported outcomes from a study of UroShield® that was conducted at the University of Southampton in the United Kingdom.

Key Points: 
  • NanoVibronix, Inc. (NASDAQ: NAOV), a medical device company that produces the UroShield®, PainShield® and WoundShield® Surface Acoustic Wave (SAW) Portable Ultrasonic Therapeutic Devices, today cited positive reported outcomes from a study of UroShield® that was conducted at the University of Southampton in the United Kingdom.
  • We are pleased to learn that through an independent study, researchers witnessed positive outcomes from the use of UroShield both in the lab and with patients.
  • Quantitative data from the research indicated a positive effect of UroShield on catheter-associated urinary tract infections (CAUTI) and catheter blockage with approximately one-third of patients in the study citing a reduction in the frequency of catheter blockages and the need for unscheduled catheter challenges.
  • It is designed to prevent biofilm formation, decrease bacteriuria/UTI, reduce catheter pain and discomfort and increase antibiotic efficacy.